Enhabit, Inc. (NYSE:EHAB) Receives $8.75 Consensus Target Price from Analysts

Enhabit, Inc. (NYSE:EHAB) has received a consensus recommendation of “Hold” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.75.

EHAB has been the topic of several research reports. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and raised their price objective for the stock from $8.25 to $9.50 in a report on Monday, December 9th. Leerink Partners restated a “market perform” rating and issued a $8.00 price target (down from $8.50) on shares of Enhabit in a report on Tuesday, November 19th.

Insider Buying and Selling at Enhabit

In other Enhabit news, Director Jeffrey Bolton bought 4,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $8.69 per share, with a total value of $34,760.00. Following the completion of the acquisition, the director now directly owns 98,144 shares of the company’s stock, valued at $852,871.36. This represents a 4.25 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stuart M. Mcguigan bought 15,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was acquired at an average cost of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the purchase, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Franklin Resources Inc. grew its holdings in shares of Enhabit by 19.6% in the third quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock valued at $256,000 after purchasing an additional 5,317 shares in the last quarter. WINTON GROUP Ltd purchased a new position in shares of Enhabit during the second quarter worth about $955,000. Marshall Wace LLP purchased a new stake in shares of Enhabit in the 2nd quarter valued at about $1,941,000. Systematic Financial Management LP boosted its holdings in shares of Enhabit by 12.2% in the third quarter. Systematic Financial Management LP now owns 1,838,199 shares of the company’s stock valued at $14,522,000 after acquiring an additional 199,235 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Enhabit during the 3rd quarter worth $215,000.

Enhabit Stock Performance

NYSE:EHAB opened at $7.60 on Wednesday. Enhabit has a 1 year low of $6.85 and a 1 year high of $11.74. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46. The stock’s 50 day simple moving average is $7.82 and its two-hundred day simple moving average is $8.14. The company has a market cap of $382.16 million, a price-to-earnings ratio of -3.28 and a beta of 1.82.

Enhabit (NYSE:EHAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter last year, the firm earned $0.03 EPS. As a group, equities analysts anticipate that Enhabit will post 0.22 earnings per share for the current fiscal year.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.